Blood test could help spot brain tumor growth vs. treatment side effects
NCT ID NCT07417774
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is part of a larger trial testing an oxygen-boosting drug called NanO2 in people with glioblastoma, a serious brain cancer. Researchers will analyze blood samples from 40 patients to find markers that show how low oxygen levels in the tumor affect the disease. They also hope to find a way to tell the difference between true tumor growth and pseudoprogression, which looks like growth on scans but is actually a treatment reaction.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NanO2 (oxygen therapeutic)
What this could lead to
If successful, this could help doctors tell the difference between actual tumor growth and treatment-related changes in glioblastoma patients, leading to more accurate monitoring.
What could go wrong
This is a small, early-stage biomarker study, not a treatment trial. The findings may not lead to immediate clinical changes or benefit participants directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Neurosciences
Tucson, Arizona, 85718, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Saint Luke's Cancer Institute
Kansas City, Missouri, 64111, United States
-
Yale Cancer Center
New Haven, Connecticut, 06520, United States